방사선종양학

본문글자크기
  • [Radiother Oncol.] Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

    성균관의대 / 유정일, 임도훈*

  • 출처
    Radiother Oncol.
  • 등재일
    2018 Nov
  • 저널이슈번호
    129(2):306-312. doi: 10.1016/j.radonc.2018.07.002. Epub 2018 Jul 20.
  • 내용

    바로가기  >

    Abstract
    BACKGROUND AND PURPOSE:
    To investigate the role of adjuvant concurrent chemo-radiotherapy (CCRT) by analyzing the outcomes of adjuvant CCRT versus chemotherapy alone (CA) in patients with D2-resected gastric cancer with lymph node (LN) metastasis.

    MATERIALS AND METHODS:
    Patients with gastric cancer from the institutional registry who underwent curative D2 and R0 resection from December 2004 to January 2013 followed by adjuvant CCRT or CA and demonstrated pathologically confirmed LN metastasis without distant metastasis were included in the study.

    RESULTS:
    A total of 1633 patients were included (909 patients in the adjuvant CCRT group and 724 patients in the CA group), and median follow-up was 65.4 months (range, 3.9-141.7 months). There was a significant difference in age (p < 0.0001), Lauren's classification (p = 0.02), number of LN metastases (p < 0.0001), and pN stage (p < 0.0001) between the CCRT and CA groups. During follow-up, recurrence was detected in 419 (25.7%) of patients overall, 236 (26.0%) in the CCRT group, and 183 (25.3%) in the CA group. Recurrence-free survival (RFS) was not significantly different between the CCRT and CA groups in univariable analysis (p = 0.92). After adjustment, pT/pN stage and perineural invasion showed statistical significance in multivariable Cox regression analysis; however, RFS was significantly higher in the CCRT group (p = 0.03, hazard ratio 0.801, 95% confidence interval 0.658-0.975).

    CONCLUSIONS:
    The adjusted RFS was significantly higher in the CCRT group than the CA group in patients with D2 resected LN metastatic gastric cancer.

     


    Author information

    Yu JI1, Lim DH2, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Lee SJ3, Kim S4, Sohn TS4, Lee JH4, An JY4, Choi MG4, Bae JM4, Kim HS5, Ahn S6.
    1
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    2
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: dh8.lim@samsung.com.
    3
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    4
    Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
    5
    Statistics and Data Center, Samsung Medical Center, Seoul, Republic of Korea.
    6
    Department of Mathematics, Ajou University, Suwon, Republic of Korea.

  • 키워드
    Adjuvant; Chemotherapy; Concurrent chemo-radiotherapy; Gastric cancer; Recurrence
  • 덧글달기
    덧글달기
       IP : 3.135.190.232

    등록